-0.1%
LIN vs MRNA
+444.4%
-444.5%
-19.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.4% | -3.4% | +3.0% | -0.4% |
| 7D | -4.0% | -10.1% | +6.1% | -3.9% |
| 30D | -4.9% | +126.7% | -131.7% | -5.8% |
| 3M | -9.2% | +184.1% | -193.3% | -10.5% |
| 6M | -2.6% | +143.3% | -145.8% | -3.7% |
| YTD | +10.5% | +359.9% | -349.3% | +7.0% |
| 1Y | -0.1% | +454.2% | -454.3% | -3.3% |
| All | -0.1% | +444.4% | -444.5% | -3.3% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling